Phathom Pharmaceuticals, Inc.
PHAT
$10.58
-$0.21-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -221.25M | -274.55M | -330.15M | -345.79M | -334.33M |
| Total Depreciation and Amortization | 633.00K | 698.00K | 733.00K | 758.00K | 795.00K |
| Total Amortization of Deferred Charges | 3.01M | 2.83M | 2.65M | 2.41M | 2.19M |
| Total Other Non-Cash Items | 63.20M | 71.25M | 74.60M | 77.13M | 79.87M |
| Change in Net Operating Assets | -12.38M | -25.46M | -22.52M | -17.19M | -15.30M |
| Cash from Operations | -166.78M | -225.23M | -274.69M | -282.68M | -266.77M |
| Capital Expenditure | -229.00K | -147.00K | -164.00K | -113.00K | -135.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -229.00K | -147.00K | -164.00K | -113.00K | -135.00K |
| Total Debt Issued | -- | 24.75M | 24.75M | 49.50M | 59.40M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.64M | 1.67M | 123.43M | 123.37M | 123.37M |
| Repurchase of Common Stock | -1.93M | -564.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -288.00K | 25.86M | 148.18M | 172.87M | 182.77M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -167.29M | -199.52M | -126.67M | -109.92M | -84.13M |